B+
Bull case
30%
Probability
Target price
$44.00
+5.0% vs current
XOMA
XOMA RoyaltyBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$40.00
-4.5% vs current
B-
Bear case
25%
Probability
Target price
$31.00
-26.0% vs current
AI sentiment snapshot
Latest data as of 2026-05-03
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+42.4
Score
AI commentary
This 2026-05-03 T+3 follow-up remains a cautious merger-monitoring memo, not a fresh standalone earnings thesis. Primary company materials confirmed the April 27, 2026 merger announcement, and XOMA's investor-relations SEC filings page showed merger and ownership filings through May 1, 2026, but no clearly available Q1 2026 earnings release or 10-Q in the checked sources, so earnings-specific revision evidence remains unavailable. The May 1, 2026 anchor price of $41.38 above the $39.00 cash leg suggests the market is pricing some CVR value and/or higher close odds, while trusted news coverage was concentrated on the acquisition rather than on operating earnings digestion.
RankAlpha Sentiment Codex - 2026-05-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystDeal spread and implied CVR value can reprice as filings and approvals developMedium impact
With the May 1, 2026 anchor price at $41.38, the market is valuing XOMA above the $39.00 cash leg, implying some combination of closing confidence and CVR value; incremental merger-related filings, shareholder process updates, and any clearer framing of the litigation-linked CVR can move that spread meaningfully over the next several weeks [#8-K-2026-04-27].
2026-09-30eventLigand merger closing and CVR terms dominate near-term valueMedium impact
XOMA agreed to be acquired by Ligand for $39.00 per share in cash plus one CVR per share tied to 75% of certain net proceeds from pending Janssen/TREMFYA litigation, with closing expected in Q3 2026 subject to stockholder and regulatory approvals; this remains the main valuation driver rather than standalone royalty execution [#8-K-2026-04-27].
2026-12-31catalystIf the deal breaks, standalone value falls back to partner-driven royalty catalystsHigh impact
If the transaction does not close, investors would likely refocus on XOMA's underlying royalty portfolio and 2026 pipeline events, including volixibat Phase 2b data in PSC in Q2 2026, ersodetug Phase 3 data in tumor HI in 2H 2026, and potential EMA decisions on OJEMDA and MIPLYFFA; however, monetization remains partner-controlled and timing is less direct than a signed cash deal [#10-K-2026-03-18].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-03 • Updated nightlySource: Internal modelMethodology